Oxaliplatin
- Generic Name
- Oxaliplatin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C8H14N2O4Pt
- CAS Number
- 61825-94-3
- Unique Ingredient Identifier
- 04ZR38536J
- Background
Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking. However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects. The DACH moiety also prevents cross-resistance with cisplatin and carboplatin.
Although oxaliplatin has been investigated as a monotherapy, it is typically administered in combination with fluorouracil and leucovorin, known as the FOLFOX regimen, for the treatment of colorectal cancer. This is an effective combination treatment both as a first-line treatment and in patients refractory to an initial fluorouracil and leucovorin combination. Ongoing trials have also shown promising results for oxaliplatin use in nonHodgkin’s lymphoma, breast cancer, mesothelioma, and non-small cell lung cancer.
Oxaliplatin was approved by the FDA on January 9, 2004 and is currently marketed by Sanofi-Aventis under the trademark Eloxatin®.
- Indication
Oxaliplatin, in combination with infusional fluorouracil and leucovorin, is indicated for the treatment of advanced colorectal cancer and adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor.
- Associated Conditions
- Advanced Colorectal Cancer, Stage III Colon Cancer
- Associated Therapies
- -
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2015-12-09
- Lead Sponsor
- Hoosier Cancer Research Network
- Target Recruit Count
- 25
- Registration Number
- NCT00216021
- Locations
- 🇺🇸
Medical & Surgical Specialists, LLC, Galesburg, Illinois, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
🇺🇸Helen F. Graham Cancer Center, Newark, Delaware, United States
Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 39
- Registration Number
- NCT00217581
- Locations
- 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2013-11-25
- Target Recruit Count
- 24
- Registration Number
- NCT00215982
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
🇵🇷San Juan Veterans Hospital, Rio Piedras, Puerto Rico
Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-05-02
- Lead Sponsor
- Hoosier Cancer Research Network
- Target Recruit Count
- 11
- Registration Number
- NCT00216073
- Locations
- 🇺🇸
Medical & Surgical Specialists, LLC, Galesburg, Illinois, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
🇺🇸Quality Cancer Center (MCGOP), Indianapolis, Indiana, United States
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3610
- Registration Number
- NCT00217737
- Locations
- 🇺🇸
UM Saint Joseph Medical Center, Towson, Maryland, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Saint Luke's Hospital, Maumee, Ohio, United States
Feasibility Study of mFOLFOX6 in Patients With Advanced Colorectal Cancer
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2006-04-21
- Lead Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
- Target Recruit Count
- 30
- Registration Number
- NCT00209703
- Locations
- 🇯🇵
Hokkaido University Hospital (Hokkaido University Graduate School of Medicine), Sapporo, Hokkaido, Japan
Phase I Trial of huA33 Plus Chemotherapy in Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 20
- Registration Number
- NCT00199797
- Locations
- 🇨🇭
UniversitaetsSpital Zuerich, Zurich, Switzerland
🇩🇪Krankenhaus Nordwest, Frankfurt, Germany
Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2013-11-11
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 48
- Registration Number
- NCT00193609
- Locations
- 🇺🇸
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
🇺🇸Greenview Regional Hospital, Bowling Green, Kentucky, United States
🇺🇸Baton Rouge General Medical Center, Baton Rouge, Louisiana, United States
A Study of Pemetrexed Plus Oxaliplatin as First Line Therapy in Advanced Gastric Carcinoma
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 43
- Registration Number
- NCT00192088
- Locations
- 🇮🇹
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-371-615-4559) Mon - Fri from 9 AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Verona, Italy
Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 36
- Registration Number
- NCT00193219
- Locations
- 🇺🇸
St. Louis Cancer Care, Chesterfield, Missouri, United States
🇺🇸Jackson Oncology Associates, Jackson, Mississippi, United States
🇺🇸Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.